Compare Incyte Corporation (INCY) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Open Text Corporation — how do they compare? Incyte Corporation trades at $112.64 (market cap $22.85B), while Open Text Corporation trades at $23.63 (market cap $5.61B). The key difference: Incyte Corporation is far larger — about 4.1× Open Text Corporation's market cap, and Open Text Corporation pays a 4.82% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Open Text Corporation for 23 Days on average.
| INCY | OTEX | |
|---|---|---|
Market Cap | $22.85B | $5.61B |
Volume | 1,927,029 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $129.93 | $39.69 |
52-Week Low | $83.80 | $20.01 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $18.35B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
OTEX trades at $23.52, up 1.64% today, with a bearish technical signal despite recent earnings beats. The stock is attractively valued with a P/E of 9.01 and P/S of 1.1, supported by strong profitability margins. Recent news highlights debt restructuring and a strategic AI partnership with Cohere, while cash flow trends show operational strength but negative net cash flow.
The outlook is mixed: valuation discounts and cloud growth present opportunity, but high debt and bearish technicals pose risks. Analyst consensus is a Buy with a $28.30 target, implying potential upside, though execution on AI initiatives and debt management will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
